Have a feature idea you'd love to see implemented?
Let us know!
SAGE Sage Therapeutics Inc
Price (delayed)
$6.73
Market cap
$410.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.41
Enterprise value
$311.05M
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing
Highlights
The company's debt has shrunk by 84% YoY and by 57% QoQ
The net income has increased by 25% year-on-year and by 11% since the previous quarter
SAGE's equity is down by 36% YoY and by 11% from the previous quarter
SAGE's quick ratio is down by 19% QoQ and by 9% YoY
Key stats
What are the main financial stats of SAGE
Market
Valuations
Earnings
Shares outstanding
61.05M
Market cap
$410.87M
Enterprise value
$311.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.64
Price to sales (P/S)
4.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.2
Revenue
$97.24M
EBIT
-$445.67M
EBITDA
-$444.29M
Free cash flow
-$373.87M
Per share
Balance sheet
Liquidity
EPS
-$7.41
Free cash flow per share
-$6.18
Book value per share
$10.44
Revenue per share
$1.61
TBVPS
$11.52
Total assets
$697.11M
Total liabilities
$69.04M
Debt
$1.41M
Equity
$628.06M
Working capital
$617.77M
Debt to equity
0
Current ratio
9.95
Quick ratio
9.53
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
-456.9%
Gross margin
95.5%
Net margin
-458.3%
Operating margin
-496.6%
Return on assets
-54.1%
Return on equity
-60.4%
Return on invested capital
-72.2%
Return on capital employed
-71%
Return on sales
-458.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SAGE stock price
How has the Sage Therapeutics stock price performed over time
Intraday
-20.64%
1 week
-12.03%
1 month
-6.79%
1 year
-63.84%
YTD
-68.94%
QTD
-6.79%
Financial performance
How have Sage Therapeutics's revenue and profit performed over time
Revenue
$97.24M
Gross profit
$92.84M
Operating income
-$482.9M
Net income
-$445.67M
Gross margin
95.5%
Net margin
-458.3%
Sage Therapeutics's operating margin has surged by 92% YoY and by 17% QoQ
The company's net margin has surged by 92% YoY and by 17% QoQ
The net income has increased by 25% year-on-year and by 11% since the previous quarter
Sage Therapeutics's operating income has increased by 22% YoY and by 11% from the previous quarter
Growth
What is Sage Therapeutics's growth rate over time
Valuation
What is Sage Therapeutics stock price valuation
P/E
N/A
P/B
0.64
P/S
4.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.2
Sage Therapeutics's EPS has increased by 25% YoY and by 12% from the previous quarter
The P/B is 61% less than the 5-year quarterly average of 2.1 and 42% less than the last 4 quarters average of 1.4
SAGE's equity is down by 36% YoY and by 11% from the previous quarter
SAGE's P/S is 97% below its 5-year quarterly average of 198.3 and 85% below its last 4 quarters average of 35.7
The revenue has increased by 7% from the previous quarter
Efficiency
How efficient is Sage Therapeutics business performance
Sage Therapeutics's ROS has soared by 92% YoY and by 17% from the previous quarter
The ROIC has contracted by 26% YoY
Sage Therapeutics's ROE has decreased by 21% YoY
SAGE's ROA is down by 18% year-on-year
Dividends
What is SAGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SAGE.
Financial health
How did Sage Therapeutics financials performed over time
The total assets has declined by 36% year-on-year and by 9% since the previous quarter
Sage Therapeutics's total liabilities has decreased by 29% YoY but it has increased by 12% QoQ
The company's debt is 100% lower than its equity
The debt to equity has plunged by 100% YoY
The company's debt has shrunk by 84% YoY and by 57% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.